X4 Pharmaceuticals (XFOR) Receivables - Other (2018 - 2025)
X4 Pharmaceuticals' Receivables - Other history spans 8 years, with the latest figure at $715000.0 for Q3 2025.
- For Q3 2025, Receivables - Other fell 33.36% year-over-year to $715000.0; the TTM value through Sep 2025 reached $715000.0, down 33.36%, while the annual FY2024 figure was $640000.0, 13.88% up from the prior year.
- Receivables - Other reached $715000.0 in Q3 2025 per XFOR's latest filing, down from $720000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $1.2 million in Q4 2022 to a low of $393000.0 in Q3 2023.
- Average Receivables - Other over 5 years is $778315.8, with a median of $747000.0 recorded in 2021.
- Peak YoY movement for Receivables - Other: plummeted 56.77% in 2023, then soared 173.03% in 2024.
- A 5-year view of Receivables - Other shows it stood at $747000.0 in 2021, then skyrocketed by 54.22% to $1.2 million in 2022, then crashed by 51.22% to $562000.0 in 2023, then increased by 13.88% to $640000.0 in 2024, then increased by 11.72% to $715000.0 in 2025.
- Per Business Quant, the three most recent readings for XFOR's Receivables - Other are $715000.0 (Q3 2025), $720000.0 (Q2 2025), and $665000.0 (Q1 2025).